A Study of the TheraBionic P1 Device in Breast Cancer (NCT07218432)
A Window of Opportunity Pilot Study: TheraBionic P1 Device for Patients With Resectable Early-stage Breast Cancer in a Neoadjuvant Setting
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.
Who can join: Review the eligibility criteria below.
Location: Karmanos Cancer Institute at McLaren Clarkston — Clarkston, Michigan
Age range: 22 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Karmanos Cancer Institute at McLaren Clarkston — Clarkston, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- Karmanos Cancer Institute Weisberg Cancer Treatment Center — Farmington Hills, Michigan
- Karmanos Cancer Institute at McLaren Flint — Flint, Michigan
- Karmanos Cancer Institute at McLaren Greater Lansing — Lansing, Michigan
- Karmanos Cancer Institute at McLaren Lapeer Region — Lapeer, Michigan
- Karmanos Cancer Institute at McLaren Northern Michigan — Petoskey, Michigan
- Karmanos Cancer Institute at McLaren Port Huron — Port Huron, Michigan
📞 Contact the Study Coordinator
Phone: (248) 922-6650
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer Stage I
- Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection — Little Rock, Arkansas
- Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT) — Washington D.C., District of Columbia
Explore by condition: All Breast Cancer Stage I clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.